{"preliminary_commentary":{"by_channel":{"podcast":2,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["cisplatin"]],"indication":"FIGO stage III epithelial ovarian cancer","name":"OVHIPEC-2","nct_id":"NCT03772028","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ovhipec-2-nct03772028. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"OVHIPEC-2","arms":[{"description":"Primary cytoreductive surgery without HIPEC","label":"conventional surgery","type":"NO_INTERVENTION"},{"description":"Primary cytoreductive surgery with HIPEC with cisplatin","label":"HIPEC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12-01","type":"ESTIMATED"},"conditions":["Ovarian Cancer"],"enrollment":{"count":538,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"cisplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-08","lead_sponsor":"The Netherlands Cancer Institute","official_title":"Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-04-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"overall survival","timeFrame":"1 year after last patient last visit"}],"references":[{"citation":"Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23.","pmid":"32205449","type":"DERIVED"}],"start_date":{"date":"2020-01-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","url":"https://clinicaltrials.gov/study/NCT03772028"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ovhipec-2-nct03772028"}